Anvatabart opadotin
As of the edition of 20 October 2026, Anvatabart opadotin is an antibody drug conjugate: in active development; acts on ERBB2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody drug conjugate
- Registered trials
- 12, 2 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Digestive system; Lungs and airways; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Anvatabart opadotin.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | P04626 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 9 | 0 | 6 | 1 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Zhejiang Medicine | Lead sponsor of trials | 2016 to now |
| Johnson & Johnson | Lead sponsor of trials | 2018 to now |